Ticker LaunchUplisting · BIVI
Biovie Inc.
Formerly NANOANTIBIOTICS, INC.
Biovie Inc. (BIVI), already reporting to the SEC, moved up to Nasdaq on Sep 18, 2020 with an offering at $10.00 per share raising $15.7M. ThinkEquity was lead-left underwriter, joined by Kingswood and Benchmark. Loeb & Loeb advised the company.
BioVie Inc. is a clinical-stage company developing drug therapies, focused on BIV201, a continuous infusion of terlipressin for ascites caused by chronic liver cirrhosis. Terlipressin is approved in about 40 countries for related complications but is not yet available in the United States.
- Status
- Uplisting
- Ticker
- BIVI
- Exchange
- Nasdaq
- Listed
- Sep 18, 2020
- Price
- $10.00
- Raised
- $15.7M
- Market cap at IPO price
- $135.8M
- First filed
- Aug 15, 2013
- Underwriters
- ThinkEquity, Kingswood and Benchmark
- Company counsel
- Loeb & Loeb
- Sector
- Biotech & pharma
- Country / state
- NV
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Aug 15, 2013
- Latest amendment Sep 8, 2020
- Final prospectus (424B4) Sep 18, 2020
- All filings on EDGAR CIK 1580149
Other Biotech & pharma uplistings in 2020
- Cyclo Therapeutics, Inc.CTDH · Dec 11, 2020 · $12.5M
- Nomad Power Solutions, Inc.LIXT · Nov 27, 2020
- Processa Pharmaceuticals, Inc.PCSA · Oct 5, 2020 · $19.2M
- GeoVax Labs, Inc.GOVX · Sep 28, 2020 · $12.8M
- Panbela Therapeutics, Inc.SNBP · Aug 31, 2020
- Windtree Therapeutics Inc /de/WINTD · May 21, 2020 · $20M